In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: Implications for the control of graft-versus-host disease

Transplantation

Volumn 79, Issue 6, 2005, Pages 722-725

  Collin, Matthew P ^a   Munster, David ^b   Clark, Georgina ^b   Wang, Xiao Nong ^a   Dickinson, Anne M ^a   Hart, Derek N ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

CMRF 44; Dendritic cell; Graft versus host disease

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; COMPLEMENT; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CMRF 44; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; DONOR; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LANGERHANS CELL; LYSIS; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE; TARGET CELL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS; CELL MOVEMENT; COMPLEMENT SYSTEM PROTEINS; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN M; LANGERHANS CELLS;

EID: 16244421996     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000149321.86104.C4     Document Type: Article

References (20)

1. Shlomchik WD. Antigen presentation in graft-vs-host disease. Exp Hematol 2003; 31: 1187.
2. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510.
3. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003; 54: 29.
4. Hakim FT, Gress RE. Reconstitution of thymic function after stem cell transplantation in humans. Curr Opin Hematol 2002; 9: 490.
5. Hock BD, Starling GC, Daniel PB, et al. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 1994; 83: 573.
6. Fearnley DB, McLellan AD, Mannering SI, et al. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody, implications for studies on antigen-presenting cell function and immunotherapy. Blood 1997; 89: 3708.
7. McLellan AD, Heiser A, Sorg RV, et al. Dermal dendritic cells associated with T lymphocytes in normal human skin display an activated phenotype. J Invest Dermatol 1998; 111: 841.
8. Koppi T, Munster DJ, Brown L, et al. CMRF-44 antibody-mediated depletion of activated human dendridic cells: a potential means for improving allograft survival. Transplantation 2003; 75: 1723.
9. Summers KL, Hock BD, McKenzie JL, et al. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am J Pathol 2001; 159: 285.
10. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161: 526.
11. Romani N, Lenz A, Glassel H, et al. Cultured human Langerhans cells resemble lymphoid dendritic cells in phenotype and function. J Invest Dermatol 1989; 93: 600.
12. Larsen CP, Steinman RM, Witmer-Pack M, et al. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483.
13. Waldmann H, Polliak A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483.
14. Hale G, Cobbold S, Novitzky N, et al. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy 2001; 3: 145.
15. Dyer MJ, Hale G, Hayhoe FG, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431.
16. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404.
17. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586.
18. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 1422.
19. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715.
20. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98: 2819.